![]() |
|
#1
|
|||
|
|||
![]() Medtronic received FDA approval for its Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan cardiac resynchronization therapy defibrillators, making them the only MRI-Conditional CRT-Ds so far to be available in the U.S. The indications allow scans of any part of the body, given certain precautions are taken. The implants work with the company’s Attain Perfoma MRI SureScan Quadripolar Leads that have themselves received FDA approval to be compatible with MRI scans. From Medtronic: The Amplia MRI device features the AdaptivCRT® algorithm, which has been shown to reduce a patient’s odds of a heart failure hospital readmission (within 30 days) by 59 percent (versus echo-optimized CRT). The AdaptivCRT feature also has been shown to improve CRT response rate by 12 percent, and to reduce AF risk by 46 percent compared to echo-optimized BiV pacing.Via: Medtronic… The post Medtronic’s MRI-Conditional CRT-Ds Approved by FDA appeared first on Medgadget. ??????? ??????: Medtronic’s MRI-Conditional CRT-Ds Approved by FDA || ??????: rss || ??????: اسم منتداك
|
![]() |
|
|